Biotech News

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Structure Therapeutics (GPCR)Structure Therapeutics2026-05-07 20:06 ESTEarnings

Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially comparable efficacy to injectable GLP1-RAs Data from ACCESS OLE expected in Q3 2026; Data from the

Open original release

Related news

AVTXAvalo Therapeutics2026-05-13 11:00 EST

Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

GRIGRI Bio2026-05-14 08:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

KYMRKymera2026-04-30 11:00 EST

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

NRIXNurix Therapeutics2026-04-08 10:00 EST

Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

KYMRKymera2026-04-23 11:00 EST

Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026

SABSSAB Biotherapeutics2026-05-12 11:30 EST

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SNGXSOLIGENIX2026-05-08 11:30 EST

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

ZURAZura Bio2026-05-07 11:30 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

KNSAKiniksa2026-04-28 11:30 EST

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

AVTXAvalo Therapeutics2026-03-23 11:00 EST

Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates

View all latest news

Structure Therapeutics

Structure Therapeutics is a GPCR-focused company developing oral small-molecule therapies for metabolic and inflammatory diseases. Its platform aims to combine validated biology with convenient dosing.

Recent company news

GPCRStructure Therapeutics2026-05-26 20:05 EST

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

GPCRStructure Therapeutics2026-05-07 20:06 EST

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

GPCRStructure Therapeutics2026-04-27 20:05 EST

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

GPCRStructure Therapeutics2026-04-14 20:05 EST

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

GPCRStructure Therapeutics2026-03-16 11:00 EST

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Stock data

Close: 48.69 USD
Market cap: 2.64B USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States